Acacia Pharma Group plc (ACPH.BR)

0.888 €

0.00 (-%)
Rating:
Recommendation:
-
Symbol ACPH.BR
Price 0.888 €
Beta 1.789
Volume Avg. 0.40M
Market Cap 89.634M
Shares () -
52 Week Range 0.7-2.775
1y Target Est -
DCF Unlevered ACPH.BR DCF ->
DCF Levered ACPH.BR LDCF ->
ROE -38.43% Strong Sell
ROA -27.52% Sell
Operating Margin -
Debt / Equity 139.74% Buy
P/E -
P/B 2.53 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Michael Bolinder
Healthcare
Biotechnology
Brussels

Acacia Pharma Group plc discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, invasive procedures, or chemotherapy treatments in the United States and internationally. The company's lead product is BARHEMSYS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also include BYFAVO, an intravenous remimazolam and reversible IV sedative designed for use during invasive medical procedures, such as colonoscopy and bronchoscopy; and APD403, a selective dopamine antagonist amisulpride that has completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting. Acacia Pharma Group plc was founded in 2007 and is based in Cambridge, the United Kingdom.